Type 2 diabetes and bariatric surgery have one of the strongest evidence records in all of obesity medicine. In randomized trials, people who had surgery were far more likely to reach near-normal blood sugar, and to need fewer medicines, than people treated with medicines alone. Some go into remission, meaning normal blood sugar with no diabetes medication. Remission isn't guaranteed and can fade over the years, so the realistic goal is better control for longer, with lifelong follow-up.
How does bariatric surgery improve type 2 diabetes?
Two things happen at once.
First, weight loss improves insulin resistance. Type 2 diabetes develops when the body's cells stop responding well to insulin and the pancreas can't keep up. Losing a large amount of weight, especially around the abdomen and liver, makes cells more responsive again.
Second, the gut itself changes. Surgery alters how food moves through the stomach and intestines, which changes gut hormones involved in appetite and blood sugar. This is why some people see their sugars improve within days of surgery, long before much weight has come off. It's also why international diabetes organizations started calling it "metabolic surgery," not just weight-loss surgery.
Diabetes is not a character flaw, and neither is needing surgery to treat it. It's a medical condition with a medical tool.
What does the research actually show?
The best evidence comes from randomized trials, where patients are assigned to surgery or medicines by chance.
- STAMPEDE (US, 5 years). 150 people with type 2 diabetes and a BMI of 27 to 43 were assigned to intensive medical therapy alone or medical therapy plus surgery. At five years, an A1C of 6.0% or lower was reached by 29% of gastric bypass patients and 23% of sleeve patients, compared with 5% on medicines alone. Surgery patients also cut their insulin use by about a third.1
- Rome trial (10 years). In 60 patients with long-standing diabetes, 25% of gastric bypass patients were still in remission at 10 years, compared with 5.5% of medically treated patients. People who had surgery also had far fewer diabetes-related complications.2
- Swedish Obese Subjects study (15 years). In this large matched study, 72% of surgery patients were in remission at two years, compared with 16% of the comparison group. At 15 years, 30% of surgery patients were still in remission versus 6.5%. Surgery patients also had roughly half the rate of small-blood-vessel complications, the kind that damage eyes, kidneys, and nerves.3
Read those numbers together and an honest picture appears. Surgery works much better than medicines alone, and the benefit to your organs seems to last even when strict remission doesn't.
Does diabetes come back after bariatric surgery?
Sometimes, yes. In the 10-year Rome trial, more than half of the patients who were in remission at two years saw their blood sugar rise again later. But every one of them still had good control at 10 years, with an average A1C of 6.7%.2
"I never promise a patient their diabetes will go away. What I tell them is that surgery usually makes it much easier to control, and that checking your A1C doesn't stop just because the numbers look good."
— Dr. Luis Pasten, Lead Bariatric Surgeon, Pompeii Surgical
That pattern is common. Diabetes that returns after surgery is usually milder and easier to manage than before. That is a real benefit, but it means "remission" is not the same as "cured." Keep checking your A1C, keep your follow-up appointments, and treat diabetes as a condition you manage for life.
Gastric sleeve or gastric bypass for diabetes?
For diabetes specifically, the evidence leans toward the gastric bypass.
"When someone has had diabetes for years or is already on insulin, I often talk with them about a bypass. For milder diabetes, or when reflux or other health issues point the other way, a sleeve can still be the better fit."
— Dr. Luis Pasten, Lead Bariatric Surgeon, Pompeii Surgical
- In the Oseberg trial from Norway, 109 people with type 2 diabetes were randomly assigned to a bypass or a sleeve. At one year, the bypass group's remission rate was 27 percentage points higher.4
- In STAMPEDE, the bypass group also did somewhat better than the sleeve group at five years (29% versus 23% reaching the A1C target).1
That doesn't make the sleeve a poor choice. It still improves diabetes substantially, it's a simpler operation, and it may suit people with milder diabetes or reasons to avoid rerouting the intestines. Your surgeon weighs how long you've had diabetes, whether you use insulin, any reflux, and your other health conditions. You can compare the two on our gastric bypass and gastric sleeve pages.
Who is most likely to go into remission?
A few things predict a better chance:
- Not yet needing insulin. In a study used to build the DiaRem score, insulin use before surgery was the strongest single predictor against remission.5
- A lower A1C going in.
- Younger age, and needing fewer or simpler diabetes medicines.
In that study, 88% of patients with the lowest-risk scores went into remission, compared with 2% of those with the highest scores.5 The lesson is about timing, not blame. Surgery tends to work best earlier, before diabetes has progressed to needing insulin. If you're on insulin, surgery can still improve control and cut your medicines. Remission is just less likely.
Can I qualify with a lower BMI if I have diabetes?
Yes, and this is where many people have outdated information. The 2022 guidelines from the American Society for Metabolic and Bariatric Surgery (ASMBS) and the International Federation for the Surgery of Obesity (IFSO) say surgery should be considered for people with metabolic disease from a BMI of 30, and is recommended for anyone from a BMI of 35.6 The American Diabetes Association's 2025 Standards of Care likewise say to consider metabolic surgery for people with diabetes and a BMI of 30 or more (27.5 or more for Asian American individuals).7 An earlier international consensus on diabetes surgery was formally endorsed by 45 medical and scientific societies.8
In everyday numbers, for someone who is 5 feet 8 inches tall, a BMI of 30 is about 197 pounds and a BMI of 35 is about 230 pounds.
What happens to my diabetes medicines around surgery?
This is the most important safety section in this article.
"With diabetic patients, the biggest safety risk I watch for isn't the operation itself, it's the medicines afterward. Sugars can drop quickly once you're eating small amounts, so I want every patient to leave with a clear plan and a doctor at home who will adjust their doses with them."
— Dr. Luis Pasten, Lead Bariatric Surgeon, Pompeii Surgical
- Some medicines must be stopped days before surgery. Drugs in the SGLT2 inhibitor class (generic names end in "-gliflozin") carry an FDA labeling instruction to pause them before surgery because of a risk of ketoacidosis. For ertugliflozin, for example, the label says at least four days.9
- After surgery, the danger often flips to low blood sugar. You'll be eating very little, and your insulin sensitivity improves quickly. Doses of insulin and some pills usually need to come down, sometimes right away.
- GLP-1 medicines such as semaglutide are also reviewed before surgery. If you're weighing them against surgery, our GLP-1 vs surgery calculator lays out the long-term costs.
Your care team adjusts every one of these. Never stop or change a diabetes medicine on your own. Check your blood sugar as instructed, and report readings that run low.
Who should not have surgery, or needs a specialist first?
- Type 1 diabetes or very low insulin production. Surgery can help weight and insulin needs, but it won't put type 1 diabetes into remission.
- Very poorly controlled sugars. A high A1C raises the risk of infection and slow healing. Your team may want it brought down first.
- Advanced kidney, heart, or eye disease from diabetes needs specialist clearance.
- Untreated eating disorders or substance use should be addressed before surgery.
Traveling to Mexico for surgery with diabetes
If you're coming to Tijuana for surgery, prepare a little extra:
- Bring your numbers. A recent A1C, your glucose log or continuous glucose monitor data, and a complete medication list with doses.
- Pack your diabetes supplies in your carry-on. Bring your meter or monitor, strips, insulin if you use it, and quick sugar for lows. Keep insulin in its original labeled packaging.
- Arrange follow-up at home before you leave. Your primary doctor or endocrinologist will need to keep adjusting your medicines as you lose weight. The ADA recommends ongoing monitoring after metabolic surgery at least every 6 to 12 months.7
At Pompeii Surgical you don't need a referral from your doctor to start, and the surgical approval review is free.
Is weight-loss surgery right for you?
If you've been adding medicines year after year and your A1C still isn't where you want it, it's reasonable to ask whether surgery belongs in your plan. Start with our quick qualification check to see whether you're in the range where guidelines support it.
If you'd like a surgeon to look at your diabetes history and medicines, you can apply here, with no pressure and no commitment. Our pricing page shows what's included up front.
Key takeaway
For people with type 2 diabetes and obesity, bariatric surgery is backed by long-term randomized trials. It improves blood sugar far more than medicines alone, often reduces or removes the need for diabetes medicine, and lowers the risk of complications. Gastric bypass tends to produce higher remission rates than the sleeve. Remission is most likely earlier in the disease and can fade with time, so follow-up and medicine adjustments are part of the deal for life.
Last reviewed and updated on October 2, 2026. This article is educational and is not medical advice; talk with your own doctor about your situation.
-
Schauer PR, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. New England Journal of Medicine. 2017. https://pmc.ncbi.nlm.nih.gov/articles/PMC5451258/ ↩↩
-
Mingrone G, et al. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2021. https://doi.org/10.1016/S0140-6736(20)32649-0 ↩↩
-
Sjöström L, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014. https://doi.org/10.1001/jama.2014.5988 ↩
-
Hofsø D, et al. Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (Oseberg): a single-centre, triple-blind, randomised controlled trial. Lancet Diabetes & Endocrinology. 2019. https://doi.org/10.1016/S2213-8587(19)30344-4 ↩
-
Still CD, et al. Preoperative prediction of type 2 diabetes remission after Roux-en-Y gastric bypass surgery: a retrospective cohort study. Lancet Diabetes & Endocrinology. 2014. https://pmc.ncbi.nlm.nih.gov/articles/PMC3932625/ ↩↩
-
Eisenberg D, et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery. Obesity Surgery. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC9834364/ ↩
-
American Diabetes Association Professional Practice Committee. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes—2025. Diabetes Care. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11635032/ ↩↩
-
Rubino F, et al. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Obesity Surgery. 2017. https://doi.org/10.1007/s11695-016-2457-9 ↩
-
U.S. Food and Drug Administration. STEGLATRO (ertugliflozin) prescribing information. 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209803s008lbledt.pdf ↩